Ferhanoğlu, BurhanGülbaş, ZaferUzay, AntÖzcan, MuhitÖzkalemkaş, FahirDal, Mehmet SinanKalyon, HakanAkay, Olga MeltemDeveci, BurakBekoz, HüseyinSevindik, Ömür GökmenToptaş, TayfurYılmaz, Asu FergünKoyun, DeryaAlkış, NihanBirtaş Ateşoğlu, Elif2023-03-102023-03-102022Ferhanoğlu, B., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F., Dal, M. S. ... Birtaş Ateşoğlu, E. (2022). Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data. Blood içinde (6704-6705. ss.). https://doi.org/10.1182/blood-2022-1653850006-49711528-0020https://doi.org/10.1182/blood-2022-165385https://hdl.handle.net/20.500.12511/10604Abstract INTRODUCT ?ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response (CR) following firstline treatment with rituximab and chemotherapy, about 40% of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R). Autologous stem-cell transplantation (ASCT) can cure some of these patients but many patients cannot undergo this procedure. CAR-T therapies are a significant advance but not available in many countries like Turkey. In Phase II expansion study, the overall response rate (ORR) was 51.6% and complete remission (CR) rate was 39.4% in R/R DLBCL patients (Dickinson er al. JCO 2022). In this retrospective study, we aimed to report the outcomes of patients who used glofitamab via compessionate use in Turkey.eninfo:eu-repo/semantics/openAccessRelapsed/RefractoryReal World DataDiffuse Large B CellConference Object140Supplement: 16704670510.1182/blood-2022-165385Q1000893223206319